Comparative Pharmacology
Head-to-head clinical analysis: ORA TESTRYL versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORA TESTRYL versus TESULOID.
ORA-TESTRYL vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
Intramuscular injection: 50-100 mg every 2-4 weeks.
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category C
Category C
Androgen
Androgen